The present disclosure relates to the development of a targeted deliverysystem for the oraldelivery of probiotics or therapeutic agent for various indications, includingand not limited toactive and prophylaxis treatment of Clostridium difficile infection,antibiotic associated diarrhea,irritable bowel syndrome, Crohn's disease, intestinal flora replacement,supplemental floratreatments for patients taking antibiotics, and for restoration of balance andsignaling betweenthe intestinal microbiome and the intestinal cells in patients under treatmentof metabolicsyndrome manifestations, specifically diabetes, insulin resistance, obesity,hyperlipidemia andhypertension. Certain embodiments restore altered probiotic organismimbalances that arecharacteristic of said diseases among others as well as defines a platformtechnologydevelopment for site specific delivery of probiotic organisms in the GI tractof a mammal, mostspecifically the ileum and/or right colon of a human subject.
